SCOPUS 정보 검색 플랫폼

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 153-156

Corrigendum to "A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors" [Bioorg. Med. Chem. Lett. 20 (2010) 153] (DOI:10.1016/j.bmcl.2009.11.021);A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors

(9) Wang, Tiansheng a Ledeboer, Mark W a Duffy, John P a Pierce, Albert C a Zuccola, Harmon J a Block, Eric a Shlyakter, Dina a Hogan, James K a Bennani, Youssef L a

a VERTEX PHARMACEUTICALS (United States)

Author keywords

Azaindole; Deazapurine; Inhibitor; JAK2; Kinase

Indexed keywords

4 (2 ANILINOPHENYL) 7 AZAINDOLE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; 7 AZAINDOLE DERIVATIVE; ALDEHYDE DERIVATIVE; AZAINDOLE; BENZALDEHYDE; DEAZAPURINE DERIVATIVE; INDOLE DERIVATIVE; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; IC 50; PICTET SPENGLER REACTION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 72049086669 PISSN: 0960894X EISSN: None Source Type: Journal
DOI: 10.1016/j.bmcl.2010.02.078 Document Type: Erratum

Times cited : (49)

References (18)

1
- 27144452311
- For general review of JAK protein kinase inhibitors, see:
- For general review of JAK protein kinase inhibitors, see:. Thompson J.E. Drug News Perspect. 18 (2005) 305
- (2005) Drug News Perspect. , vol.18 , pp. 305
- Thompson, J.E.¹

2
- 35648947759
- Sorbera L.A., Serradell N., Bolos J., Rosa E., and Bozzo J. Drugs Future 32 (2007) 674
- (2007) Drugs Future , vol.32 , pp. 674
- Sorbera, L.A.¹ Serradell, N.² Bolos, J.³ Rosa, E.⁴ Bozzo, J.⁵

3
- 17844383458
- James C., Ugo V., Le Couedic J.-P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. Nature 434 (2005) 1144
- (2005) Nature , vol.434 , pp. 1144
- James, C.¹ Ugo, V.² Le Couedic, J.-P.³ Staerk, J.⁴ Delhommeau, F.⁵ Lacout, C.⁶ Garcon, L.⁷ Raslova, H.⁸ Berger, R.⁹ Bennaceur-Griscelli, A.¹⁰ Villeval, J.L.¹¹ Constantinescu, S.N.¹² Casadevall, N.¹³ Vainchenker, W.¹⁴

4
- 20244369569
- Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J.P., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsberger J., Koo S., Lee J., Gabriel S., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.J., Meyerson M., Golub T.R., Lee S.J., and Gilliland D.G. Cancer Cell 7 (2005) 387
- (2005) Cancer Cell , vol.7 , pp. 387
- Levine, R.L.¹ Wadleigh, M.² Cools, J.³ Ebert, B.L.⁴ Wernig, G.⁵ Huntly, B.J.P.⁶ Boggon, T.J.⁷ Wlodarska, I.⁸ Clark, J.J.⁹ Moore, S.¹⁰ Adelsberger, J.¹¹ Koo, S.¹² Lee, J.¹³ Gabriel, S.¹⁴ Marynen, P.¹⁵ Vandenberghe, P.¹⁶ Mesa, R.A.¹⁷ Tefferi, A.¹⁸ Griffin, J.D.¹⁹ Eck, M.J.²⁰ more..

5
- 17644424955
- Kralovics R., Passamonti F., Buser A.S., Teo S.-S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. N. Eng. J. Med. 352 (2005) 1779
- (2005) N. Eng. J. Med. , vol.352 , pp. 1779
- Kralovics, R.¹ Passamonti, F.² Buser, A.S.³ Teo, S.-S.⁴ Tiedt, R.⁵ Passweg, J.R.⁶ Tichelli, A.⁷ Cazzola, M.⁸ Skoda, R.C.⁹

6
- 20144363192
- Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Lancet 365 (2005) 1054
- (2005) Lancet , vol.365 , pp. 1054
- Baxter, E.J.¹ Scott, L.M.² Campbell, P.J.³ East, C.⁴ Fourouclas, N.⁵ Swanton, S.⁶ Vassiliou, G.S.⁷ Bench, A.J.⁸ Boyd, E.M.⁹ Curtin, N.¹⁰ Scott, M.A.¹¹ Erber, W.N.¹² Green, A.R.¹³

7
- 20744460045
- Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., and Zhao Z.J. J. Biol. Chem. 280 (2005) 22788
- (2005) J. Biol. Chem. , vol.280 , pp. 22788
- Zhao, R.¹ Xing, S.² Li, Z.³ Fu, X.⁴ Li, Q.⁵ Krantz, S.B.⁶ Zhao, Z.J.⁷

8
- 85044559381
- Tono C., Xu G., Toki T., Takahashi Y., Sasaki S., Terui K., and Ito E. Leukemia 19 (2005) 1843
- (2005) Leukemia , vol.19 , pp. 1843
- Tono, C.¹ Xu, G.² Toki, T.³ Takahashi, Y.⁴ Sasaki, S.⁵ Terui, K.⁶ Ito, E.⁷

9
- 30844444135
- Tefferi A., Lasho T.L., Schwager S.M., Steensma D.P., Mesa R.A., Li C.-Y., Wadleigh M., and Gilliland D.G. Br. J. Haematol. 131 (2005) 320
- (2005) Br. J. Haematol. , vol.131 , pp. 320
- Tefferi, A.¹ Lasho, T.L.² Schwager, S.M.³ Steensma, D.P.⁴ Mesa, R.A.⁵ Li, C.-Y.⁶ Wadleigh, M.⁷ Gilliland, D.G.⁸

10
- 68149160994
- For recent review on Jak2 inhibitors in potential treatment of myeloproliferative disorders, see:
- For recent review on Jak2 inhibitors in potential treatment of myeloproliferative disorders, see:. Atallah E., and Verstovsek S. Exp. Rev. Anticancer Ther. 9 (2009) 663
- (2009) Exp. Rev. Anticancer Ther. , vol.9 , pp. 663
- Atallah, E.¹ Verstovsek, S.²

11
- 72049119168
- Takenaka K. Ketsueki, Shuyoka 58 (2009) 70
- (2009) Ketsueki, Shuyoka , vol.58 , pp. 70
- Takenaka, K.¹

12
- 38349053791
- Pardanani A. Leukemia 22 (2008) P23
- (2008) Leukemia , vol.22
- Pardanani, A.¹

13
- 61849124057
- Skoda R.C. Blood 111 (2008) 5419
- (2008) Blood , vol.111 , pp. 5419
- Skoda, R.C.¹

14
- 39649099388
- Morgan K.J., and Gilliland D.G. Annu. Rev. Med. (2008) 59 213
- (2008) Annu. Rev. Med.
- Morgan, K.J.¹ Gilliland, D.G.²

15
- 0004571867
- For a review of the Ergot alkaloids, see:. Brossi A. (Ed), Academic Press, San Diego, CA
- For a review of the Ergot alkaloids, see:. Ninomiya I., and Kiguchi T. In: Brossi A. (Ed). The Alkaloids Vol. 38 (1990), Academic Press, San Diego, CA 1
- (1990) The Alkaloids , vol.38 , pp. 1
- Ninomiya, I.¹ Kiguchi, T.²

16
- 0037194618
- For the preparation of 21c, see:
- For the preparation of 21c, see:. Chen Y.T., and Seto C.T. J. Med. Chem. 45 (2002) 3946
- (2002) J. Med. Chem. , vol.45 , pp. 3946
- Chen, Y.T.¹ Seto, C.T.²

17
- 72049107896
- JAK2 Ki Determination: ATP and polyE4Y were obtained from Sigma Chemical Co, St. Louis, MO, USA, 33P-γ-ATP, GF/B filter plates, and Ultima Gold™ scintillant were purchased from Perkin-Elmer Life Sciences (Boston, MA, USA, JAK2 used in Vertex assays were expressed and purified by the Gene Expression and Protein Biochemistry groups, respectively, at Vertex Pharmaceuticals Incorporated using standard recombinant methods.a Methods: The inhibitory activity of compounds in Table 1 against JAK2 was determined by following the residual kinase activity of JAK2 using a radiometric assay. The final concentration of the components in the assay were as follows: 100 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM DTT, 0.01% BSA, 0.6 nM JAK2, 0.5 mg/ml polyE4Y, and 12 μM 33P-γ-ATP. A stock solution of inhibitor was made up in DMSO from which additional dilutions were made in DMSO; a 1.5 μL aliquot of DMSO or inhibitor in DMSO was
- 2 using Prism software, version 4.0, San Diego, CA, USA. (a) Fox, T.; Coll, J. T.; Ford, P. J.; Germann, U. A.; Porter, M. D.; Pazhanisamy, S.; Fleming, M. A.; Galullo, V.; Su, M.-S.; Wilson, K. P. Protein Sci. 1998, 7, 2249; (b) Morrison, J. F.; Stone, S. R. Comments Mol. Cell Biophys. 1985, 2, 347.

18
- 72049128700
- note
- 50 values were calculated with Softmax Pro (Molecular Devices, Sunnyvale CA).

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.